- ICH GCP
- 미국 임상 시험 레지스트리
- 임상시험 NCT00452075
Erlotinib as First-line Treatment of Advanced Non-small Cell Lung Cancer (NSCLC) for Patients Unfit for Chemotherapy
A Phase II Study of Erlotinib and Predictive Markers as First-line Treatment of Advanced Non-small Cell Lung Cancer for Patients Unfit for Chemotherapy
A phase II study of Tarceva (Erlotinib) and predictive markers as first-line treatment of advanced non-small cell lung cancer for patients unfit for chemotherapy (NSCLC) Clinical Phase II Stage IIIB or IV non-small cell lung cancer (NSCLC) Primary end point: Disease control rate (= CR+PR and SD at 8 weeks /patients). Secondary end point: Safety (Serious Adverse Events, Adverse Events leading to premature withdrawal, unexpected TarcevaTM related AEs) .Correlation of EGFR expression rate (HER1) and FISH potentially predictive for response.
An open-label, non randomized, multicenter, clinical trial of TarcevaTM as single agent The sample size is 29 patients in 2 stages and based on Simon´s optimal 2 stage design. Stage 1 will accrue 10 patients, if less than 1 response is observed the study will stop; if more than 1 response is observed the accrual will continue up till 29 patients. A total of 29 patients would be entered and the treatment will be declared to have sufficient activity to deserve further attention if at least 5 patients obtain disease control.
연구 개요
연구 유형
등록 (실제)
단계
- 2 단계
연락처 및 위치
연구 장소
-
-
-
Copenhagen, 덴마크, 2100
- Department of Oncology, Rigshospitalet
-
Odense, 덴마크, 5000
- Department of Oncology, Odense University Hospital
-
Århus, 덴마크, 8000
- Department of Oncology, Århus University Hospital
-
-
참여기준
자격 기준
공부할 수 있는 나이
건강한 자원 봉사자를 받아들입니다
연구 대상 성별
설명
Inclusion Criteria:
- Histological or cytological documented diagnosis of inoperable, locally advanced, recurrent or metastatic (Stage IIIB or Stage IV) NSCLC.
- Chemo-naïve patients.
- Patients who are in the investigator's opinion not medically suitable for chemotherapy.
- Measurable disease according to the RECIST criteria.
- ECOG performance status of 0 - 3.
- Life expectancy of at least 12 weeks.
- Patients must be able to take oral medication.
- Serum calcium within normal ranges
- ≥ 4 weeks since prior surgery or radiation therapy
- For all females of childbearing potential a negative pregnancy test must be obtained within 48 hours before starting therapy and must use effective contraception
- 18 years of age or older
- Written (signed) Informed Consent to participate in the study
Exclusion Criteria:
- Prior systemic antitumor therapy
- Any unstable systemic disease which according to the investigator contraindicates the use of the study drug render the subject at high risk from treatment complications (including active infection, unstable angina, myocardial infarction within the previous month, inflammatory bowel disease, hepatic disease with serum bilirubin ≥ 2 upper limit of normal (ULN) or AST and/or ALT ≥ 2 x ULN (or ≥ 5 x ULN if clearly attributable to liver metastasis), renal disease with acute renal failure or serum creatinine ≥ 5 x ULN.
- Any other malignancies within 5 years (except for adequately treated carcinoma in situ of the cervix or basal or squamous cell skin cancer).
- Nursing mothers or pregnant woman.
- Hypersensitivity to Tarceva or co-formulants.
- Patients with brain metastasis or spinal cord compression that has not yet been definitively treated with surgery and/or radiation.
- Patients with brain metastasis or spinal cord compression that not are in a stable condition despite treatment with steroids.
공부 계획
연구는 어떻게 설계됩니까?
디자인 세부사항
- 주 목적: 치료
- 할당: 무작위화되지 않음
- 중재 모델: 단일 그룹 할당
- 마스킹: 없음(오픈 라벨)
무기와 개입
참가자 그룹 / 팔 |
개입 / 치료 |
|---|---|
|
실험적: arm 1 medicine
erlotinib daily
|
150mg daily
다른 이름들:
|
연구는 무엇을 측정합니까?
주요 결과 측정
결과 측정 |
기간 |
|---|---|
|
Disease control rate
기간: 2010
|
2010
|
2차 결과 측정
결과 측정 |
기간 |
|---|---|
|
To investigate the tolerability and safety of erlotinib in patients, who can not receive chemotherapy, by registration of side-effects.
기간: 2010
|
2010
|
|
Correlation of EGFR expression rate and FISH potentially predictive for response
기간: 2010
|
2010
|
공동 작업자 및 조사자
수사관
- 수석 연구원: Pappot Helle, MD, DMSC, Department of Oncology, Rigshospitalet, Denmark
연구 기록 날짜
연구 주요 날짜
연구 시작
기본 완료 (실제)
연구 완료 (실제)
연구 등록 날짜
최초 제출
QC 기준을 충족하는 최초 제출
처음 게시됨 (추정)
연구 기록 업데이트
마지막 업데이트 게시됨 (추정)
QC 기준을 충족하는 마지막 업데이트 제출
마지막으로 확인됨
추가 정보
이 정보는 변경 없이 clinicaltrials.gov 웹사이트에서 직접 가져온 것입니다. 귀하의 연구 세부 정보를 변경, 제거 또는 업데이트하도록 요청하는 경우 register@clinicaltrials.gov. 문의하십시오. 변경 사항이 clinicaltrials.gov에 구현되는 즉시 저희 웹사이트에도 자동으로 업데이트됩니다. .